


Express Mail Label No.: EV 669114445 US

Atty. Dkt. No. 351325-0102

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Saragovi et al.
Title: Compound Targeted For Specific
Cells With Reduced Systemic
Toxicity
Appl. No.: 10/600,623
Filing Date: 6/20/2003
Examiner: Brandon J. Fetterolf
Art Unit: 1642
Confirmation Number: 7195

CERTIFICATE OF EXPRESS MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service's "Express Mail Post Office To Addressee" service under 37 C.F.R. § 1.10 on the date indicated below and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
EV 669114445 US	June 21, 2006
(Express Mail Label Number)	(Date of Deposit)
Devora L. Gavel	
(Printed Name)	
	
(Signature)	

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to

06/26/2006 MAHME1 00000046 10600623

03 FC:1806

180.00 0P

BOST_205508.1

antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(d), before payment of the issue fee.

RELEVANCE OF EACH DOCUMENT

The relevance of the foreign-language documents is described in the present specification. An English translation of the foreign-language documents is not readily available. However, the absence of such translation does not relieve the PTO from its duty to consider the submitted foreign language documents (37 CFR §1.98 and MPEP §609).

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

FEE

A credit card payment form in the amount of \$180.00 is enclosed in accordance with 37 CFR §1.17(p) to cover the fee associated with an information disclosure statement under 37 CFR §1.97(d) in the amount of \$180.00.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to

Express Mail Label No.: EV 669114445 US


Atty. Dkt. No. 351325-0102

Deposit Account No. 50-3431 Ref. 351325-0102. Should no proper payment be enclosed herewith, as by the credit card payment form being unsigned, providing incorrect information resulting in a rejected credit card transaction, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-3431 Ref. 351325-0102.

Respectfully submitted,

Date June 21, 2006

FOLEY & LARDNER LLP
Customer Number: 48329
Telephone: (617) 342-4088
Facsimile: (617) 342-4001

By 
James F. Ewing
Attorney for Applicant
Registration No. 52,875

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 351325-0102	SERIAL NO. 10/600,623
(Use several sheets if necessary)		APPLICANT SARAGOVI et al.	
		FILING DATE 6/20/2003	GROUP ART UNIT 1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A-1	4,997,913	03-05-1991	Hellstrom, et al.			
	A-2	5,084,560	01-28-1992	Hellstrom, et al.			
	A-3	5,208,323	05-04-1993	Page et al.			
	A-4	5,869,045	02-09-1999	Hellstrom, et al.			
	A-5	6,020,145	02-01-2000	Hellstrom, et al.			
	A-6	6,030,997	02-29-2000	Eilat et al.			
	A-7	6,140,100	10-31-2000	Smith et al.			
	A-8	6,812,209	11-2-2004	Sinn et al.			

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	B-1	EP 0 294 294 A2	06-03-1988					
	B-2	WO-00/33888	06-15-2000					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	C-1	Trail P.A., et al. XP002203755, ISSN: 1078-0432 "Enhanced antitumor activity of paclitaxel. . immunoconjugate BR96-doxorubicin" November 1999, vol. 5, no. 11 pp 3632-3638.
	C-2	Dubowchik G.M., et al. XP004143756, ISSN: 0960-894X " Cathespin B-sensitive dipeptide prodrugs. . and doxorubicin" December 1998, vol. 8, no. 23, pp 3347-3352.
	C-3	Tewey K.M., et al. "Adriamycin—induced DNA damage mediated by mammalian DNA topoisomerase II" Department of Biological Chemistry, April 1983, Science, vol. 226; pp 466-468
	C-4	Zhang D. W., et al. "Identification of an amino acid residue. . . to anthracyclines" The Journal of Biological Chemistry, vol. 276, no. 16 issue April 2001, pp 1323-1329.
	C-5	Guillemard V., et al. "Taxane-antiboy conjugates afford potent cytotoxicity, enhanced. . . tumor target selectivity" Cancer Research, 61, January 15, 2001, pp 694-699.
	C-6	Saragovi H. U., et al. "Development of pharmacological agents for targeting neurotrophins and their receptors" Elsevier Science Ltd. Vol. 21, March 2000, pp 93-98.
	C-7	LeSauter L., et al. "Potent human p140-trkA agonists derived from an anti-receptor monoclonal antibody" The journal of neuroscience, February 15, 1996, 16(4), pp 1308-1316.

EXAMINER	DATE CONSIDERED
----------	-----------------

- * EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.